Chris Feierabend

1.0k total citations
27 papers, 820 citations indexed

About

Chris Feierabend is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chris Feierabend has authored 27 papers receiving a total of 820 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chris Feierabend's work include Cancer Treatment and Pharmacology (15 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer therapeutics and mechanisms (4 papers). Chris Feierabend is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer therapeutics and mechanisms (4 papers). Chris Feierabend collaborates with scholars based in United States, Spain and Germany. Chris Feierabend's co-authors include Dona Alberti, George Wilding, R Z Arzoomanian, K D Tutsch, Howard H. Bailey, Rhoda Arzoomanian, Kendra D. Tutsch, Marcia Pomplun, Gregory H. Ripple and Rebecca Marnocha and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Chris Feierabend

27 papers receiving 792 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chris Feierabend United States	14	375	364	129	111	60	27	820
Hisao Fukumoto Japan	17	587 1.6×	432 1.2×	193 1.5×	129 1.2×	29 0.5×	30	1.0k
Karin Barnouin United Kingdom	14	543 1.4×	500 1.4×	145 1.1×	96 0.9×	28 0.5×	22	1.1k
O. Michael Colvin United States	15	337 0.9×	197 0.5×	73 0.6×	73 0.7×	41 0.7×	23	790
Rhoda Arzoomanian United States	15	510 1.4×	319 0.9×	148 1.1×	160 1.4×	30 0.5×	27	947
Sühendan Ekmekçioğlu United States	15	403 1.1×	278 0.8×	110 0.9×	139 1.3×	33 0.6×	22	839
Kendra D. Tutsch United States	19	773 2.1×	502 1.4×	182 1.4×	207 1.9×	44 0.7×	39	1.5k
Marie-Christine Bissery France	17	432 1.2×	724 2.0×	164 1.3×	173 1.6×	42 0.7×	23	1.2k
Jaideep V. Thottassery United States	18	570 1.5×	565 1.6×	59 0.5×	142 1.3×	53 0.9×	31	1.2k
Nicholas Brown United Kingdom	10	608 1.6×	300 0.8×	85 0.7×	388 3.5×	37 0.6×	10	1.1k
Wanghai Zhang United States	11	387 1.0×	249 0.7×	67 0.5×	72 0.6×	35 0.6×	16	683

Countries citing papers authored by Chris Feierabend

Since Specialization

Citations

This map shows the geographic impact of Chris Feierabend's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Feierabend with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Feierabend more than expected).

Fields of papers citing papers by Chris Feierabend

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Feierabend. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Feierabend. The network helps show where Chris Feierabend may publish in the future.

Co-authorship network of co-authors of Chris Feierabend

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Feierabend. A scholar is included among the top collaborators of Chris Feierabend based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Feierabend. Chris Feierabend is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mulkerin, Daniel, Noelle K. LoConte, Kyle D. Holen, et al.. (2009). A phase I study of an oral simulated FOLFOX with high dose capecitabine. Investigational New Drugs. 27(5). 461–468. 6 indexed citations

Dubey, Sarita, Paul R. Hutson, Dona Alberti, et al.. (2005). Phase I study of docetaxel and topotecan in patients with advanced malignancies. Journal of Oncology Pharmacy Practice. 11(4). 132–138. 2 indexed citations

Wilding, George, David K. King, Kendra D. Tutsch, et al.. (2004). Phase I Trial of the Polyamine Analog N1,N14-Diethylhomospermine (DEHSPM) in Patients with Advanced Solid Tumors. Investigational New Drugs. 22(2). 131–138. 11 indexed citations

Wilding, George, K D Tutsch, R Z Arzoomanian, et al.. (2004). A phase I trial of perillyl alcohol administered four times daily for 14�days out of 28�days. Cancer Chemotherapy and Pharmacology. 54(4). 25 indexed citations

Dubey, Sarita, Michael N. Gould, Kendra D. Tutsch, et al.. (2003). Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemotherapy and Pharmacology. 52(5). 361–366. 21 indexed citations

Liu, Glenn, Howard H. Bailey, Rhoda Arzoomanian, et al.. (2003). Gemcitabine, Paclitaxel, and Piritrexim. American Journal of Clinical Oncology. 26(3). 280–284. 3 indexed citations

Thomas, James P., Kendra D. Tutsch, James F. Cleary, et al.. (2002). Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemotherapy and Pharmacology. 50(6). 465–472. 100 indexed citations

Thomas, James P., Daniel Mulkerin, Jordan Berlin, et al.. (2002). Phase I Study of Eniluracil, Oral 5-Fluororacil and Gemcitabine in Patients with Advanced Malignancy. Investigational New Drugs. 20(4). 377–382. 2 indexed citations

Liu, Glenn, Jordan Berlin, Kendra D. Tutsch, et al.. (2002). Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy.. PubMed. 8(3). 706–11. 2 indexed citations

10.

Thomas, James, Rhoda Arzoomanian, Dona Alberti, et al.. (2001). Phase I clinical and pharmacokinetic trial of irofulven. Cancer Chemotherapy and Pharmacology. 48(6). 467–472. 16 indexed citations

11.

Robins, H. Ian, Dörthe M. Katschinski, Walter Longo, et al.. (1999). A pilot study of melphalan, tumor necrosis factor-α and 41.8 °C whole-body hyperthermia. Cancer Chemotherapy and Pharmacology. 43(5). 409–414. 10 indexed citations

12.

Robins, H. Ian, Kendra D. Tutsch, Elaine L. Jacobson, et al.. (1999). Phase I Trial of Intravenous Thymidine and Carboplatin in Patients With Advanced Cancer. Journal of Clinical Oncology. 17(9). 2922–2922. 5 indexed citations

13.

Berlin, Jordan, Dona Alberti, Rhoda Arzoomanian, et al.. (1998). A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors. Investigational New Drugs. 16(4). 325–330. 33 indexed citations

14.

Berlin, Jordan, Barry E. Storer, K D Tutsch, et al.. (1998). Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy.. Journal of Clinical Oncology. 16(3). 1142–1149. 5 indexed citations

15.

Cleary, James F., et al.. (1997). A phase I study of 5-fluorouracil, leucovorin and levamisole. Cancer Chemotherapy and Pharmacology. 39(4). 300–306. 5 indexed citations

16.

Berlin, Jordan, K D Tutsch, Paul R. Hutson, et al.. (1997). Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor.. Journal of Clinical Oncology. 15(2). 781–789. 44 indexed citations

17.

Bailey, Howard H., Gregory H. Ripple, K D Tutsch, et al.. (1997). Phase I Study of Continuous-Infusion L-S,R-Buthionine Sulfoximine With Intravenous Melphalan. JNCI Journal of the National Cancer Institute. 89(23). 1789–1796. 139 indexed citations

18.

Schulz, Craig, H. I. Robins, Behnam Badie, et al.. (1997). 9 Continuous 28 day iododeoxyuridine (IUdR) infusion and hyperfractionated accelerated radiotherapy (HART) for malignant glioma: A phase I clinical and thymidine replacement study. International Journal of Radiation Oncology*Biology*Physics. 39(2). 139–139. 3 indexed citations

19.

Schiller, Joan H., B. Storer, K D Tutsch, et al.. (1994). Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.. Journal of Clinical Oncology. 12(2). 241–248. 111 indexed citations

20.

Robins, H. Ian, Justin Cohen, Carol L. Schmitt, et al.. (1993). Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients.. Journal of Clinical Oncology. 11(9). 1787–1794. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact